Mutation-Specific Codon Suppression for Aging and Longevity

Mutation-specific Codon Suppression for Aging and Longevity

VITARNA

Gene Therapy

Artan Bio has proposed a novel approach to address genetic and age-related diseases caused by nonsense mutations. These mutations lead to premature protein translation stops, resulting in incomplete and nonfunctional proteins. The solution involves an engineered suppressor system that specifically recognizes these codons and restores normal protein translation.

Owned by

0x452f3…8C80d

Contract:

0x7b66E…5F9C2

Description

Team

Owner

Owner

Owner

Owner

Owner

Owner

Contributor

Experiment Cost

$91,300.00

Project Score

Updated Aug 12, 2026

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Price of VITARNA

$0.749

Project Progress

All updates

All categories

Timeline

Activity

Time	Type	$VITARNA	USD	ETH	From

Mutation-specific Codon Suppression for Aging and Longevity

VITARNA

Gene Therapy

Owned by

0x452f3…8C80d

Contract:

0x7b66E…5F9C2

Description

Team

Owner

Owner

Owner

Owner

Owner

Owner

Contributor

Experiment Cost

$91,300.00

Project Score

Updated Aug 12, 2026

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Price of VITARNA

$0.749

Project Progress

All updates

All categories

Timeline

Activity

Time	Type	$VITARNA	USD	ETH	From

Rationale

Extensive in vitro experimental work has been conducted demonstrating proof-of-mechanism (p53 protein restoration via nonsense suppression in Calu-6 cells) with dose-response data, reproducibility across multiple experiments, and appropriate controls. A preliminary in vivo mouse study (C57BL/6 wild-type) was conducted but was a safety/biodistribution study only—not a disease model efficacy study. No experiments have been performed in disease-relevant in vivo models (e.g., aged mice, progeroid models, tumor-bearing animals) or advanced disease-modeling systems (e.g., patient-derived organoids), and no therapeutic efficacy has been demonstrated in any in vivo context, keeping the project at TRL 2.

Assessment

Low Confidence

RecommendationPROMOTE

Total Score3.85

Overall Assessment

ArtanBio's Artan-102 program scores a strong 3.85/5.00 at TRL 2, reflecting a project that has generated meaningful early experimental evidence supporting its core hypothesis while maintaining a clear development trajectory. The strongest performance is in Therapeutic Relevance (4/5, weighted 1.80), where robust in vitro proof-of-concept data (Western Blot, dose-response qPCR) and preliminary in vivo biodistribution/safety data in mice substantiate the codon suppression mechanism for aging-related CGA nonsense mutations, backed by a compelling recent publication in Nature Aging. Utility of Candidates (4/5, weighted 0.80) is also strong, with Artan-102 clearly differentiated as the lead from systematic screening, two clinical-compatible vectors validated, and a Lonza GMP manufacturing pathway established — though the purification-dependent transduction/cytotoxicity trade-off requires resolution. Prospects for Safety (4/5, weighted 0.60) benefit from clean preliminary mouse CBC and body weight data plus AAV9's regulatory precedent, but the small study size and short duration limit confidence. Intellectual Property (3/5, weighted 0.45) is the weakest criterion — patent filings are completed but details on scope, claims, and freedom-to-operate in the crowded AAV IP landscape are absent. Therapeutic Optionality (4/5, weighted 0.20) is promising given the broad target landscape (p53, BRCA2, TERT, APOE, etc.) and emerging clinical pathway (post-chemo premature aging), but remains conceptual without experimental validation in alternative models. Key risks to monitor include: (1) the large-scale vs. ultra-purified AAV formulation optimization challenge, (2) the need for larger and longer-duration animal safety studies, (3) IP landscape navigation for AAV9 delivery, and (4) the ambitious timeline to Phase 1 in UAE by Q2 2026 given current fundraising status ($391K raised of $5M target). Overall, the project demonstrates solid TRL 2 performance with credible scientific foundations and a well-structured development plan, warranting continued investment and progression toward IND-enabling studies.

Weighted Score

Therapeutic Relevance

Strong early experimental results support the hypothesis. In vitro Western Blot data in Calu-6 cells (p53 R196X/R196X) confirms that Artan-102 restores p53 protein expression via codon suppression, with clear dose-response (qPCR, up to ~6.8 relative units at MOI=10^6). The biological rationale is well-supported by a recent Nature Aging 2025 publication linking somatic CpG mutations to epigenetic aging clocks, directly reinforcing the CGA>UGA nonsense mutation suppression mechanism. Preliminary in vivo mouse biodistribution data shows Artan-102 detected in all 6 key tissues (liver ~350x, brain ~4x over vehicle), confirming AAV9 tropism and systemic delivery. The October 2025 VectorBuilder transfection study further validates that both clinical-compatible vectors drive p53 expression. However, functional restoration of p53 activity (e.g., downstream pathway activation, cell cycle arrest, apoptosis induction) has not yet been demonstrated, and the therapeutic effect on aging phenotypes remains unproven — preventing a score of 5.

Therapeutic Optionality

Emerging findings suggest strong alternative applications. The CGA nonsense mutation suppression mechanism is not limited to a single target — arginine CGA codons are present in numerous age-related and disease-relevant proteins (p53, BRCA2, ATM, TERT, APOE, PINK1, PRKN, APP, etc.), spanning cancer, neurodegeneration, and rare genetic diseases (cystic fibrosis, autism). The Abu Dhabi regulatory meeting identified premature aging post-chemotherapy as a potential human proof-of-concept indication, representing a new clinical pathway. The Syenex VivoCell Platform partnership opens additional delivery modalities beyond AAV9. However, these alternative applications remain conceptual — no experimental data has been generated in alternative disease models or indications beyond the p53 Calu-6 system.

Intellectual Property

Patent filings have been completed as part of the IPT funding activities (2024), which is a positive step. The in vitro and in vivo data generated (dose-response, biodistribution, vector screening, clinical-compatible vector validation) could strengthen existing IP filings with experimental support. The first-in-class codon suppressor mechanism for aging provides a potentially novel IP position. However, the project data does not disclose the specific scope, claims, or jurisdictions of the patent filings, nor whether freedom-to-operate analyses have been conducted. AAV9 is a well-known delivery vector with existing IP landscape complexities (Spark Therapeutics, UPenn patents), and the use of Lonza's Xcite platform and Syenex's VivoCell Platform may introduce third-party IP dependencies. No information on granted patents or prosecution status is available, limiting confidence in IP strength.

Utility Of Candidates

Artan-102 has clearly emerged as the lead drug candidate from a systematic screening process. From an initial panel of 5 vectors, Artan-102 was identified as the top performer via Western Blot (strongest p53 induction) and confirmed via dose-response qPCR. The August 2025 VectorBuilder study further characterized 6 AAV9 variants across 3 vector constructs, revealing important purification-dependent differences (large-scale vs. ultra-purified) in transduction efficiency and cytotoxicity. Two clinical-compatible vectors (VB250610-1157tpv and VB250610-1162rmu) have been validated for p53 expression in the October 2025 transfection study. AAV9 encapsulation is confirmed with viable titers (2.06E+12 to 1.54E+13 GC/ml). The Lonza manufacturing contract provides a clear GMP pathway. However, the observation that large-scale preparations show higher transduction but also more cytotoxicity vs. ultra-purified preparations (27-130x fold difference in RNA levels) introduces a formulation optimization challenge that needs resolution before candidate finalization. No efficacy data in disease-relevant animal models yet.

Prospects For Safety

Preliminary in vivo safety data in C57BL/6 mice (n=4/group, single IV dose 1.8x10^12 GC/mouse, 14 days) is encouraging: no significant body weight changes and no significant findings across all CBC parameters (WBC, neutrophils, lymphocytes, monocytes, eosinophils, basophils). This suggests an acceptable early safety profile. AAV9 has regulatory precedent (FDA-approved AAV9-based gene therapies like Zolgensma), which de-risks the delivery platform. However, the mouse study is very small (n=4/group), short duration (14 days), and uses a single dose level — insufficient for comprehensive safety assessment. The VectorBuilder bright-field microscopy data showing more cell debris with large-scale (non-purified) AAV preparations raises a cytotoxicity flag that needs to be addressed in formulation optimization. No immunogenicity, liver toxicity panels, or longer-term safety data are available. The planned non-GLP NHP tox study and subsequent GLP tox study will be critical for further safety characterization.